Overall rank by patents
#2,558
Across all tracked assignees
USPTO 2015–2025 USPTO PatentsView US Corporation
INTRA-CELLULAR THERAPIES, INC.
USPTO PatentsView assignee record — 152 granted patents across 15 technology areas, active 2015–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS).
152
Total patents granted
15
CPC technology areas
19.1
Avg claims per patent
+34%
5-year filing velocity
The verdict
INTRA-CELLULAR holds 152 US patents across 15 technology areas — rank #2,558 of 50,000 tracked assignees.
- #2,558
- of 50,000 US assignees by volume
- Top 17%
- by Innovation Score (48.4/100)
- 19.1
- avg claims per patent
- +34%
- filing velocity, last 5 yrs
Portfolio overview
INTRA-CELLULAR THERAPIES, INC. has been granted 152 US utility patents between 2015 and 2025, placing INTRA-CELLULAR THERAPIES, INC. at rank #2,558 across all assignees tracked by PlainPatent. This portfolio spans 15 distinct Cooperative Patent Classification (CPC) subclasses, averaging 19.1 claims per patent with primary concentration in A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS). As a US Corporation, INTRA-CELLULAR THERAPIES, INC. is one of the more focused assignees in the PatentsView dataset. The composite Innovation Score of 48.4/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Between 2020 and 2025 the company received 87 grants, compared with 65 in the 2015–2019 window — a +34% shift in five-year velocity. Steady filing volume suggests sustained innovation without dramatic pivots. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. INTRA-CELLULAR THERAPIES, INC.'s 19.1 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while concentration in 15 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark INTRA-CELLULAR THERAPIES, INC. against peers pursuing similar technology classes.
How does INTRA-CELLULAR compare?
Granted US patents 2015–2025 versus the largest corporate holders — this company marked ◀
- Samsung
SAMSUNG ELECTRONICS CO., LTD.
106,890 patents
- International Bus…
International Business Machines Corporation
72,926 patents
- Canon 34,378
Canon Kabushiki Kaisha
34,378 patents
- LG 32,607
LG ELECTRONICS INC.
32,607 patents
- Taiwan Semiconduc… 31,041
TAIWAN SEMICONDUCTOR MANUFACTURING COMPANY LTD.
31,041 patents
- Apple 30,560
Apple Inc.
30,560 patents
- Qualcomm Incorpor… 30,354
QUALCOMM Incorporated
30,354 patents
- Intel 27,498
Intel Corporation
27,498 patents
- Intra-cellular Th… ◀ 152
INTRA-CELLULAR THERAPIES, INC.
152 patents
What this shows INTRA-CELLULAR holds 152 patents — placing it at rank #2,558 overall, well behind the volume leaders but ahead of the tens of thousands of smaller assignees in the dataset.
INTRA-CELLULAR's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
48 Top 17% higher than 83% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView — PlainPatent Innovation Score · 2015–2025
USPTO utility patent grants by year · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2015 | 11 | 7.2% |
| 2016 | 13 | 8.6% |
| 2017 | 17 | 11.2% |
| 2018 | 12 | 7.9% |
| 2019 | 12 | 7.9% |
| 2020 | 13 | 8.6% |
| 2021 | 16 | 10.5% |
| 2022 | 11 | 7.2% |
| 2023 | 12 | 7.9% |
| 2024 | 13 | 8.6% |
| 2025 | 22 | 14.5% |
Which technologies does INTRA-CELLULAR THERAPIES, INC. patent most?
Top 15 of 15 technology areas
Patent Moat Analysis
Portfolio Volume Moderate
Tech Breadth Focused
Claim Depth Standard
Velocity Growing
Frequently Asked Questions
How many patents does INTRA-CELLULAR THERAPIES, INC. hold?
INTRA-CELLULAR THERAPIES, INC. holds 152 US granted patents filed between 2015 and 2025, spanning 15 technology areas.
What is INTRA-CELLULAR THERAPIES, INC.'s Innovation Score?
INTRA-CELLULAR THERAPIES, INC. has an Innovation Score of 48.4 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does INTRA-CELLULAR THERAPIES, INC. focus on?
INTRA-CELLULAR THERAPIES, INC.'s top technology area is A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS) with 128 patents. The company has filed patents in 15 CPC subclasses total.
Is INTRA-CELLULAR THERAPIES, INC.'s patent filing rate increasing or decreasing?
INTRA-CELLULAR THERAPIES, INC.'s recent filing velocity is +34% compared to the prior five-year period. The company is maintaining or growing its patent output.
What does claim depth mean for INTRA-CELLULAR THERAPIES, INC.'s patents?
INTRA-CELLULAR THERAPIES, INC.'s patents average 19.1 claims each. This falls within the standard range, providing solid legal coverage.
How is the INTRA-CELLULAR THERAPIES, INC. patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.
Learn More
Explore the patent dataset
A61P technology
INTRA-CELLULAR THERAPIES, INC.'s primary CPC class — all holders and yearly trends
Top 50 patent holders
See where INTRA-CELLULAR THERAPIES, INC. ranks among the largest US patent assignees
All technology classes
Browse every CPC technology area by patent activity
How the score works
The four dimensions behind the Innovation Score
Related
Data sourced from USPTO PatentsView — official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent Editorial
Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.
Read our methodology — how this data is sourced, computed, and verified.
All federal data sources used on this page
- USPTO PatentsView — official U.S. Patent and Trademark Office bulk patent data. patentsview.org
- USPTO Patent Application Information Retrieval (PAIR) — application status and file history. uspto.gov/patents/pair
- USPTO Bulk Data Storage System — comprehensive patent text + claims dataset. bulkdata.uspto.gov
- USPTO CPC Classification — Cooperative Patent Classification scheme for technology categorization. uspto.gov/cpc
- SEC EDGAR — public filings cross-reference for assignee corporate entity matching. sec.gov/edgar
- WIPO PATENTSCOPE — international patent context (related international filings). wipo.int/patentscope
